India, July 21 -- Myriad Genetics, Inc. (MYGN), a molecular diagnostics company, announced Tuesday the full commercial launch of FirstGene Multiple Prenatal Screen, a laboratory test that simultaneously performs four prenatal genetic screens from a single maternal blood draw as early as eight weeks of pregnancy.
The FirstGene screen combines fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening into a single test report, with results expected in about 10 days.
According to the company, the test is designed to streamline prenatal genetic screening by combining multiple guideline-supported tests into one order without requiring a reproductive partner sample.
The fetal chromosome screen ...